Australia seems poised to experience a groundbreaking treatment for obesity: Retatrutide. This new dual agonist – targeting on both GLP-1 and GIP receptors – has promising outcomes in international trials, suggesting substantial decreases in weight. While regulatory clearance remains with TGA, se